MEDICAL FACILITIES CORP (DR.CA) Stock Fundamental Analysis
TSX:DR • CA58457V5036
17 CAD
+0.14 (+0.83%)
Last: Feb 27, 2026, 07:00 PM
We assign a fundamental rating of 6 out of 10 to DR. DR was compared to 13 industry peers in the Health Care Providers & Services industry. DR has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. DR is cheap, but on the other hand it scores bad on growth. This makes DR very considerable for value investing!
1. Profitability
1.1 Basic Checks
- DR had positive earnings in the past year.
- In the past year DR had a positive cash flow from operations.
- Of the past 5 years DR 4 years were profitable.
- DR had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- DR's Return On Assets of 30.18% is amongst the best of the industry. DR outperforms 100.00% of its industry peers.
- The Return On Equity of DR (94.43%) is better than 100.00% of its industry peers.
- The Return On Invested Capital of DR (15.42%) is better than 92.31% of its industry peers.
- DR had an Average Return On Invested Capital over the past 3 years of 16.37%. This is significantly above the industry average of 7.74%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.18% | ||
| ROE | 94.43% | ||
| ROIC | 15.42% |
ROA(3y)8.42%
ROA(5y)6.13%
ROE(3y)25.39%
ROE(5y)18.93%
ROIC(3y)16.37%
ROIC(5y)14.6%
1.3 Margins
- The Profit Margin of DR (31.60%) is better than 100.00% of its industry peers.
- DR's Profit Margin has improved in the last couple of years.
- Looking at the Operating Margin, with a value of 15.59%, DR belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
- In the last couple of years the Operating Margin of DR has remained more or less at the same level.
- Looking at the Gross Margin, with a value of 63.75%, DR belongs to the top of the industry, outperforming 92.31% of the companies in the same industry.
- In the last couple of years the Gross Margin of DR has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.59% | ||
| PM (TTM) | 31.6% | ||
| GM | 63.75% |
OM growth 3Y-0.97%
OM growth 5Y-1.3%
PM growth 3Y78.64%
PM growth 5Y55.2%
GM growth 3Y-0.53%
GM growth 5Y-0.42%
2. Health
2.1 Basic Checks
- DR has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- Compared to 1 year ago, DR has less shares outstanding
- Compared to 5 years ago, DR has less shares outstanding
- DR has a better debt/assets ratio than last year.
2.2 Solvency
- DR has an Altman-Z score of 1.41. This is a bad value and indicates that DR is not financially healthy and even has some risk of bankruptcy.
- DR's Altman-Z score of 1.41 is fine compared to the rest of the industry. DR outperforms 61.54% of its industry peers.
- The Debt to FCF ratio of DR is 2.05, which is a good value as it means it would take DR, 2.05 years of fcf income to pay off all of its debts.
- DR's Debt to FCF ratio of 2.05 is amongst the best of the industry. DR outperforms 92.31% of its industry peers.
- A Debt/Equity ratio of 1.02 is on the high side and indicates that DR has dependencies on debt financing.
- With a Debt to Equity ratio value of 1.02, DR perfoms like the industry average, outperforming 53.85% of the companies in the same industry.
- Although DR does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.02 | ||
| Debt/FCF | 2.05 | ||
| Altman-Z | 1.41 |
ROIC/WACC1.92
WACC8.05%
2.3 Liquidity
- DR has a Current Ratio of 1.79. This is a normal value and indicates that DR is financially healthy and should not expect problems in meeting its short term obligations.
- DR has a Current ratio of 1.79. This is amongst the best in the industry. DR outperforms 100.00% of its industry peers.
- A Quick Ratio of 1.67 indicates that DR should not have too much problems paying its short term obligations.
- The Quick ratio of DR (1.67) is better than 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.79 | ||
| Quick Ratio | 1.67 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 60.81% over the past year.
- Looking at the last year, DR shows a very negative growth in Revenue. The Revenue has decreased by -41.68% in the last year.
- Measured over the past years, DR shows a decrease in Revenue. The Revenue has been decreasing by -3.59% on average per year.
EPS 1Y (TTM)60.81%
EPS 3Y10.86%
EPS 5Y0%
EPS Q2Q%-23.33%
Revenue 1Y (TTM)-41.68%
Revenue growth 3Y-5.96%
Revenue growth 5Y-3.59%
Sales Q2Q%-20.29%
3.2 Future
- Based on estimates for the next years, DR will show a small growth in Earnings Per Share. The EPS will grow by 6.63% on average per year.
- Based on estimates for the next years, DR will show a very negative growth in Revenue. The Revenue will decrease by -12.02% on average per year.
EPS Next Y24.91%
EPS Next 2Y15.15%
EPS Next 3Y10.76%
EPS Next 5Y6.63%
Revenue Next Year-20.98%
Revenue Next 2Y-10.85%
Revenue Next 3Y-7.1%
Revenue Next 5Y-12.02%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- DR is valuated reasonably with a Price/Earnings ratio of 10.43.
- 92.31% of the companies in the same industry are more expensive than DR, based on the Price/Earnings ratio.
- Compared to an average S&P500 Price/Earnings ratio of 27.10, DR is valued rather cheaply.
- DR is valuated reasonably with a Price/Forward Earnings ratio of 9.98.
- Based on the Price/Forward Earnings ratio, DR is valued cheaply inside the industry as 92.31% of the companies are valued more expensively.
- DR is valuated cheaply when we compare the Price/Forward Earnings ratio to 28.06, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.43 | ||
| Fwd PE | 9.98 |
4.2 Price Multiples
- DR's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. DR is cheaper than 100.00% of the companies in the same industry.
- 84.62% of the companies in the same industry are more expensive than DR, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.52 | ||
| EV/EBITDA | 4.77 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- DR has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)0.42
PEG (5Y)N/A
EPS Next 2Y15.15%
EPS Next 3Y10.76%
5. Dividend
5.1 Amount
- DR has a Yearly Dividend Yield of 2.14%.
- DR's Dividend Yield is a higher than the industry average which is at 1.39.
- Compared to an average S&P500 Dividend Yield of 1.83, DR has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.14% |
5.2 History
- The dividend of DR decreases each year by -19.91%.
- DR has been paying a dividend for at least 10 years, so it has a reliable track record.
- DR has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)-19.91%
Div Incr Years1
Div Non Decr Years4
5.3 Sustainability
- DR pays out 6.72% of its income as dividend. This is a sustainable payout ratio.
DP6.72%
EPS Next 2Y15.15%
EPS Next 3Y10.76%
TSX:DR (2/27/2026, 7:00:00 PM)
17
+0.14 (+0.83%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)03-12 2026-03-12
Inst Owners11.96%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap301.92M
Revenue(TTM)257.36M
Net Income(TTM)81.33M
Analysts40
Price Target16.58 (-2.47%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.14% |
Yearly Dividend0.35
Dividend Growth(5Y)-19.91%
DP6.72%
Div Incr Years1
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.6%
Min EPS beat(2)-7.54%
Max EPS beat(2)6.33%
EPS beat(4)2
Avg EPS beat(4)3.38%
Min EPS beat(4)-24.98%
Max EPS beat(4)39.71%
EPS beat(8)3
Avg EPS beat(8)-25.78%
EPS beat(12)5
Avg EPS beat(12)32.86%
EPS beat(16)7
Avg EPS beat(16)-103.27%
Revenue beat(2)1
Avg Revenue beat(2)-1.3%
Min Revenue beat(2)-4.5%
Max Revenue beat(2)1.91%
Revenue beat(4)1
Avg Revenue beat(4)-6.39%
Min Revenue beat(4)-18.84%
Max Revenue beat(4)1.91%
Revenue beat(8)3
Avg Revenue beat(8)-3.49%
Revenue beat(12)4
Avg Revenue beat(12)-2.43%
Revenue beat(16)5
Avg Revenue beat(16)-2.23%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-5.41%
EPS NQ rev (3m)9.38%
EPS NY rev (1m)0%
EPS NY rev (3m)-5.79%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.49%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.27%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.43 | ||
| Fwd PE | 9.98 | ||
| P/S | 0.86 | ||
| P/FCF | 4.52 | ||
| P/OCF | 4.16 | ||
| P/B | 2.56 | ||
| P/tB | N/A | ||
| EV/EBITDA | 4.77 |
EPS(TTM)1.63
EY9.59%
EPS(NY)1.7
Fwd EY10.02%
FCF(TTM)3.76
FCFY22.13%
OCF(TTM)4.09
OCFY24.05%
SpS19.82
BVpS6.63
TBVpS-0.87
PEG (NY)0.42
PEG (5Y)N/A
Graham Number15.6
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.18% | ||
| ROE | 94.43% | ||
| ROCE | 18.66% | ||
| ROIC | 15.42% | ||
| ROICexc | 19.71% | ||
| ROICexgc | 46.81% | ||
| OM | 15.59% | ||
| PM (TTM) | 31.6% | ||
| GM | 63.75% | ||
| FCFM | 18.99% |
ROA(3y)8.42%
ROA(5y)6.13%
ROE(3y)25.39%
ROE(5y)18.93%
ROIC(3y)16.37%
ROIC(5y)14.6%
ROICexc(3y)21.7%
ROICexc(5y)18.79%
ROICexgc(3y)53.59%
ROICexgc(5y)43.79%
ROCE(3y)19.81%
ROCE(5y)17.76%
ROICexgc growth 3Y35.06%
ROICexgc growth 5Y23.36%
ROICexc growth 3Y18.42%
ROICexc growth 5Y13.1%
OM growth 3Y-0.97%
OM growth 5Y-1.3%
PM growth 3Y78.64%
PM growth 5Y55.2%
GM growth 3Y-0.53%
GM growth 5Y-0.42%
F-Score6
Asset Turnover0.95
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.02 | ||
| Debt/FCF | 2.05 | ||
| Debt/EBITDA | 1.54 | ||
| Cap/Depr | 25.03% | ||
| Cap/Sales | 1.64% | ||
| Interest Coverage | 7.65 | ||
| Cash Conversion | 93.1% | ||
| Profit Quality | 60.09% | ||
| Current Ratio | 1.79 | ||
| Quick Ratio | 1.67 | ||
| Altman-Z | 1.41 |
F-Score6
WACC8.05%
ROIC/WACC1.92
Cap/Depr(3y)47.79%
Cap/Depr(5y)40.36%
Cap/Sales(3y)2.81%
Cap/Sales(5y)2.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.81%
EPS 3Y10.86%
EPS 5Y0%
EPS Q2Q%-23.33%
EPS Next Y24.91%
EPS Next 2Y15.15%
EPS Next 3Y10.76%
EPS Next 5Y6.63%
Revenue 1Y (TTM)-41.68%
Revenue growth 3Y-5.96%
Revenue growth 5Y-3.59%
Sales Q2Q%-20.29%
Revenue Next Year-20.98%
Revenue Next 2Y-10.85%
Revenue Next 3Y-7.1%
Revenue Next 5Y-12.02%
EBIT growth 1Y-46.1%
EBIT growth 3Y-6.86%
EBIT growth 5Y-4.85%
EBIT Next Year4.11%
EBIT Next 3Y2.42%
EBIT Next 5Y-5.32%
FCF growth 1Y-6.31%
FCF growth 3Y4.28%
FCF growth 5Y3.38%
OCF growth 1Y-24.65%
OCF growth 3Y3.26%
OCF growth 5Y1.55%
MEDICAL FACILITIES CORP / DR.CA FAQ
What is the fundamental rating for DR stock?
ChartMill assigns a fundamental rating of 6 / 10 to DR.CA.
Can you provide the valuation status for MEDICAL FACILITIES CORP?
ChartMill assigns a valuation rating of 9 / 10 to MEDICAL FACILITIES CORP (DR.CA). This can be considered as Undervalued.
Can you provide the profitability details for MEDICAL FACILITIES CORP?
MEDICAL FACILITIES CORP (DR.CA) has a profitability rating of 8 / 10.
What is the expected EPS growth for MEDICAL FACILITIES CORP (DR.CA) stock?
The Earnings per Share (EPS) of MEDICAL FACILITIES CORP (DR.CA) is expected to grow by 24.91% in the next year.
How sustainable is the dividend of MEDICAL FACILITIES CORP (DR.CA) stock?
The dividend rating of MEDICAL FACILITIES CORP (DR.CA) is 5 / 10 and the dividend payout ratio is 6.72%.